Press Release

VEGZELMA® (bevacizumab-adcd) receives preferred formulary status with Ventegra® for commercially insured patients 2023-12-11

VEGZELMA® (bevacizumab-adcd) receives preferred formulary status with Ventegra® for commercially insured patients Ventegra® will list VEGZELMA®(bevacizumab-adcd) on its national formulary that serves more than 400 clients and more than 13 million members and patients in the U.S. Celltrion USA completes a contract ...

Celltrion USA announces distribution and incorporation of YUFLYMA® (adalimumab-aaty), a Humira® biosimilar, to CarePartners Specialty Pharmacy Cost Savings Programs 2023-10-26

Celltrion USA announces distribution and incorporation of YUFLYMA® (adalimumab-aaty), a Humira® biosimilar, to CarePartners Specialty Pharmacy Cost Savings Programs YUFLYMA® (adalimumab-aaty) was first approved by the Food and Drug Administration on May ...

Celltrion USA Announces U.S. FDA Approval of ZYMFENTRA™ (infliximab-dyyb), the First and Only Subcutaneous infliximab, for the Treatment of People With Inflammatory Bowel Disease 2023-10-23

Celltrion USA Announces U.S. FDA Approval of ZYMFENTRA™ (infliximab-dyyb), the First and Only Subcutaneous infliximab, for the Treatment of People With Inflammatory Bowel Disease ZYMFENTRA™ is the first and only FDA-approved subcutaneous (SC) formulation of i...

게시물 검색

25

Celltrion receives CHMP positive opinion for trast..

The CHMP recommended Herzuma®(CT-P6) for approval in early breast cancer, metastatic breast cancer and metastatic gastric cancer SATURDAY 15 DECEMBER 07:00 CET, INCHEON, SOUTH KOREA- The Committee for Medicinal Products for Human Use (CHMP) of t…

2017-12-15
24

Top UK university hospital unveils data that suppo..

CT-P10 also proven to have pharmacokinetic equivalence to reference rituximab ATLANTA-New data from University College London Hospitals NHS Foundation Trust (UCLH) on the safety and tolerability of rapid infusion of CT-P10 were present…

2017-12-11
23

Celltrion Healthcare presents phase III switching ..

6 November 2017.San Diego, California. New data presented at the 2017 American College of Rheumatology (ACR) Annual Meeting show that CT-P10 is comparable to reference rituximab in terms of efficacy, pharmacodynamics (PD) and safety profile, over a s…

2017-11-05
22

Celltrion Healthcare present 1-year results for CT..

CT-P13 shown to be comparable in efficacy and safety to reference infliximab in switched inflammatory bowel disease patients CT-P13 shown to be well-tolerated in subcutaneous form 30 October 2017, Barcelona, Spain.Today at the 25thUnited Europe…

2017-10-30
21

Biosimilar trastuzumab candidate, CT-P6, shown to ..

8 September 2017, Madrid, Spain -Celltrion Healthcare presents data at the European Society for Medical Oncology (ESMO) 2017 Congress thathighlights similarity in efficacy and safety between CT-P6 (biosimilar trastuzumab candidate) and reference tras…

2017-09-08
20

Celltrion Healthcare: The Lancet Haematology publi..

-Data show that CT-P10 is comparable to reference rituximab in terms of efficacy and safety The Lancet Haematologypublished detailed results from the ongoing phase 3,double-blind, randomised, parallel-group, active-controlled study of CT-P10.[1] …

2017-07-13
19

Celltrion Healthcare: The Lancet Oncology publishe..

Data show that CT-P6 is comparable to reference trastuzumab in terms of efficacy and safety Tuesday, June 14 2017.Detailed results from the phase 3,double-blind, randomised, parallel-group, active-controlled study of biosimilar trastuzumab candida…

2017-06-14
18

Celltrion Healthcare showcases data supporting the..

-Truxima® is non inferior to reference rituximab in advanced follicular lymphoma (FL) - a form of non-Hodgkin lymphoma -Sustained efficacy was shown over 48 weeks irrespective of BMI in a phase III rheumatoid arthritis (RA) study that demon…

2017-06-14
17

Biosimilar trastuzumab candidate, CT-P6, shown to ..

4 June 2017, Chicago, USAData presented at the 2017 American Society of Clinical Oncology Annual Meeting has shown similarity in efficacy and safety between CT-P6 (biosimilar trastuzumab candidate) and reference trastuzumab as pre-operative (neoadjuv…

2017-06-02
16

Celltrion Healthcare Launches Remsima® Monitor Kit..

- Providing customized medical services for patients with autoimmune diseases by measuring serum drug concentration and anti-drug antibody production - 20~30% of the cost of existing therapeutic drug monitoring methods … Distinguishing Remsima®by ta…

2017-04-03

CelltrionHealthcare